Orphazyme A/S (ORPHA.CO)
| Previous close | 1.7020 |
| Open | 1.6340 |
| Bid | 1.5310 x 0 |
| Ask | 1.5510 x 0 |
| Day's range | 1.2310 - 1.6990 |
| 52-week range | 1.1000 - 109.1000 |
| Volume | |
| Avg. volume | 275,896 |
| Market cap | 56.676M |
| Beta (5Y monthly) | 1.07 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Globe Newswire
Restructuring Proposal
Orphazyme A/S in restructuringCompany announcementNo. 26/2022 Inside informationwww.orphazyme.com Company Registration No. 32266355 Copenhagen, Denmark, May 18, 2022 – Orphazyme A/S in restructuring (ORPHA.CO; ORPH) (“Orphazyme” or the “Company”), a late-stage biopharmaceutical company, announces that the enclosed restructuring proposal (the “Restructuring Proposal”) will be submitted to the Danish Maritime and Commercial High Court (the “Court”) and be sent to the Company’s known creditors foll
- Globe Newswire
Updated Financial Calendar for 2022
Orphazyme A/S in restructuringCompany announcement No. 25/2022www.orphazyme.com Company Registration No. 32266355 Copenhagen, Denmark, May 16, 2022 – Orphazyme A/S in restructuring (ORPHA.CO; ORPH) (“Orphazyme” or the “Company”), a late-stage biopharmaceutical company, announces an update to the Company’s financial calendar for the remainder of 2022 following the signing of a binding agreement with KemPharm, Inc. for sale of substantially all of the company’s assets and business activities durin
- Globe Newswire
Orphazyme A/S under In-Court-Restructuring to sell substantially all of its assets and business activities to KemPharm, Inc.
Orphazyme A/S in restructuringCompany announcementNo. 24/2022Inside informationwww.orphazyme.comCompany Registration No. 32266355 KemPharm to acquire Orphazyme assets, including those relating to the development and approval of arimoclomol, for a total of USD 12.8 million in cash and assumed liabilities estimated to equal approximately USD 5.2 millionThe majority of Orphazyme’s approximately 20 current employees will become employees at KemPharmKemPharm intends to continue to pursue approval of
